Despite recent advancements in allogeneic hematopoietic stem cell transplantation, graftversus-host disease (GVHD) remains a major cause of morbidity and mortality following transplantation. This clinical review focuses on the pathogenesis and risk factor of GVHD. On the basis of the time of presentation, cutaneous GVHD has been originally divided into an acute and chronic disease. Standard treatment of cutaneous GVHD involves the intensification of immunosuppressive therapy with adequate topical supportive management. A review of the adverse events reported in the literature revealed the need to develop evidence-based nursing practices to promote the care of this complex patient population.